Andy Greenstein

Andy Greenstein is an accomplished professional with extensive experience in scientific strategy and translational science. Currently serving as Senior Director of Scientific Strategy at Exelixis, Andy has also held significant roles such as Director and Associate Director of Translational Science at Corcept Therapeutics. Previous positions include Senior Research Scientist and Research Scientist at Gilead Sciences, where leadership in research teams focused on Andecaliximab was notable. Additionally, Andy has contributed to academia as a Doctoral Research Advisor and Thesis Committee Member at the University of Brighton. Andy's educational background includes a PhD in Biochemistry and Molecular Biology from the University of California, Berkeley, and a B.S. in Biochemistry from the University of Connecticut.